Increased renal TXA2 synthesis in diabetes mellitus: Simultaneous determination of urinary TXB2 and 2,3-dinor-TXB2

Katayama, Shigehiro; Inaba, Masaaki; Maruno, Yoshiko; Omoto, Akira; Kawazu, Shoji; Ishii, Jun; Sawada, Masafumi

doi:10.1016/0952-3278(90)90171-g

Cited by 18 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, COX generation of the platelet-activating metabolite PGF 2α is increased in Type I and Type II diabetes [24,25,58,107]. PGI 2 , measured as the urinary metabolite PGF 1α , acts as a renal vasodilator and anti-aggregatory metabolite that counteracts the injurious TXA 2 effects [25]. One consistent finding in diabetic patients and animal models has been a decreased urinary 6-keto PGF 1α /TXB 2 ratio [23,24].…”

Section: Renal Vascular Eicosanoids In Diabetes and Metabolic Syndromementioning

confidence: 96%

“…Increased TXA 2 production contributes to the progression of diabetic nephropathy by its vasoconstrictor action and induction of glomerular matrix proteins [58,[106][107][108]. Likewise, COX generation of the platelet-activating metabolite PGF 2α is increased in Type I and Type II diabetes [24,25,58,107]. PGI 2 , measured as the urinary metabolite PGF 1α , acts as a renal vasodilator and anti-aggregatory metabolite that counteracts the injurious TXA 2 effects [25].…”

Section: Renal Vascular Eicosanoids In Diabetes and Metabolic Syndromementioning

confidence: 98%

“…Additionally, TXA 2 is proaggregatory, stimulates mesangial cell matrix production and has been associated with progressive glomerular damage [25]. TXA 2 and TP receptors have been associated and implicated in the glomerular renal vascular alterations that occur during various renal disorders [3,18,25]. Thus TXA 2 and TP receptors are viable therapeutic targets for the treatment of renal vascular dysfunction.…”

Section: Overview Of Renal Haemodynamic Actions Of Eicosanoidsmentioning

confidence: 98%

“…Alterations in renal vascular PGI 2 production in disease states could contribute to the progression of kidney damage. In particular, changes in the balance between the vasoconstrictor and pro-aggregatory COX metabolite TXA 2 and PGI 2 appear to contribute to renal vascular pathology in disease states [23][24][25]. TXA 2 is a renal vasoconstrictor that is produced at low levels in the kidney under normal physiological conditions [2,26].…”

Section: Overview Of Renal Haemodynamic Actions Of Eicosanoidsmentioning

confidence: 99%

“…TP receptor activation of L-type calcium channels contributes to renal vasoconstriction in response to angiotensin [2,18]. Additionally, TXA 2 is proaggregatory, stimulates mesangial cell matrix production and has been associated with progressive glomerular damage [25]. TXA 2 and TP receptors have been associated and implicated in the glomerular renal vascular alterations that occur during various renal disorders [3,18,25].…”

Section: Overview Of Renal Haemodynamic Actions Of Eicosanoidsmentioning

confidence: 99%

See 4 more Smart Citations

Eicosanoids and renal vascular function in diseases

Imig

2006

Clinical Science

View full text Add to dashboard Cite

Arachidonic acid metabolites are vital for the proper control of renal haemodynamics and, when not properly controlled, can contribute to renal vascular injury and end-stage renal disease. Three major enzymatic pathways, COX (cyclo-oxygenase), CYP450 (cytochrome P450) and LOX (lipoxygenase), are responsible for the metabolism of arachidonic acid metabolites to bioactive eicosanoids. These eicosanoids can dilate or constrict the renal vasculature and maintain vascular resistance in the face of changing vasoactive hormones. Renal vascular generation of eicosanoids is altered in pathophysiological conditions such as hypertension, diabetes, metabolic syndrome and acute renal failure. Experimental evidence supports the concept that altered eicosanoid metabolism contributes to renal haemodynamic alterations and the development and progression of nephropathy. The possible beneficial renal vascular actions of enzymatic inhibitors, eicosanoid analogues and receptor antagonists have been examined in hypertension, diabetes and metabolic syndrome. This review highlights the roles of renal vascular eicosanoids in the pathogenesis of nephropathy and therapeutic targets for renal disease related to hypertension, diabetes, metabolic syndrome and acute renal failure.

show abstract

Section: Renal Vascular Eicosanoids In Diabetes and Metabolic Syndromementioning

confidence: 96%

Section: Renal Vascular Eicosanoids In Diabetes and Metabolic Syndromementioning

confidence: 98%

Section: Overview Of Renal Haemodynamic Actions Of Eicosanoidsmentioning

confidence: 98%

Section: Overview Of Renal Haemodynamic Actions Of Eicosanoidsmentioning

confidence: 99%

Section: Overview Of Renal Haemodynamic Actions Of Eicosanoidsmentioning

confidence: 99%

See 3 more Smart Citations

Eicosanoids and renal vascular function in diseases

Imig

2006

Clinical Science

View full text Add to dashboard Cite

show abstract

The Renal Microcirculation

Navar

Arendshorst

Pallone

et al. 2008

Comprehensive Physiology

View full text Add to dashboard Cite

Urinary biomarkers involved in type 2 diabetes: a review

Matheson¹,

Willcox

Flanagan

et al. 2010

Diabetes Metabolism Res

131

View full text Add to dashboard Cite

Diabetes mellitus is one of the most challenging health concerns of the 21st century. With at least 30% of the diabetic population remaining undiagnosed, effective and early diagnosis is of critical concern. Development of a diagnostic test, more convenient and reliable than those currently used, would therefore be highly beneficial. Urine as a diagnostic medium allows for non-invasive detection of biomarkers, including some associated with type 2 diabetes and its complications. This review provides a synopsis of those urinary biomarkers that potentially may provide a basis for the development of improved diagnostic tests. Three main pathways for the sourcing of potential makers are identified: kidney damage, oxidative stress and low-grade inflammation including atherosclerosis/vascular damage. This review briefly presents each pathway and some of the most relevant urinary biomarkers that may be used to monitor the development or progression of diabetes and its complications. In particular, biomarkers of renal dysfunction such as transferrin, type IV collagen and N-acetyl-beta-D-glucosaminidase might prove to be more sensitive than urinary albumin, the current gold standard, in the detection of incipient nephropathy and risk assessment of cardiovascular disease. Inflammatory markers including orosomucoid, tumour necrosis factor-alpha, transforming growth factor-beta, vascular endothelial growth factor and monocyte chemoattractant protein-1, as well as oxidative stress markers such as 8-hydroxy-2'deoxyguanosine may also be useful biomarkers for diagnosis or monitoring of diabetic complications, particularly kidney disease. However, the sensitivity of these markers compared with albumin requires further investigation.

show abstract

Increased renal TXA2 synthesis in diabetes mellitus: Simultaneous determination of urinary TXB2 and 2,3-dinor-TXB2

Cited by 18 publications

References 18 publications

Eicosanoids and renal vascular function in diseases

Eicosanoids and renal vascular function in diseases

The Renal Microcirculation

Urinary biomarkers involved in type 2 diabetes: a review

Contact Info

Product

Resources

About